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Abstract: All blood lineage cells are generated from hematopoietic stem cells (HSCs), which reside in
bone marrow after birth. HSCs self-renew, proliferate, and differentiate into mature progeny under
the control of local microenvironments including hematopoietic niche, which can deliver regulatory
signals in the form of bound or secreted molecules and from physical cues such as oxygen tension
and shear stress. Among these mediators, accumulating evidence indicates the potential involvement
of several chemokines, particularly CXCL12, in the interaction between HSCs and bone marrow
microenvironments. Fusion between breakpoint cluster region (BCR) and Abelson murine leukemia viral
oncogene homolog (ABL)-1 gene gives rise to BCR-ABL protein with a constitutive tyrosine kinase
activity and transforms HSCs and/or hematopoietic progenitor cells (HPCs) into disease-propagating
leukemia stem cells (LSCs) in chronic myeloid leukemia (CML). LSCs can self-renew, proliferate,
and differentiate under the influence of the signals delivered by bone marrow microenvironments
including niche, as HSCs can. Thus, the interaction with bone marrow microenvironments is
indispensable for the initiation, maintenance, and progression of CML. Moreover, the crosstalk
between LSCs and bone marrow microenvironments can contribute to some instances of therapeutic
resistance. Furthermore, evidence is accumulating to indicate the important roles of bone marrow
microenvironment-derived chemokines. Hence, we will herein discuss the roles of chemokines in
CML with a focus on bone marrow microenvironments.
Keywords: CCL3; CXCL12; CXCR4; hematopoietic stem cell; hematopoietic progenitor cell; leukemia
stem cell; niche
1. Introduction
Hematopoietic stem cells (HSCs), the only cells capable of producing all blood cell lineages,
are present in diverse tissues throughout development, beginning in the aorta-gonad-mesonephron
region and the yolk sac followed by the placenta, fetal liver, spleen, and bone marrow [1]. After
birth, the bone marrow is the primary site of hematopoiesis, which occurs through the orchestrated
proliferation, self-renewal, and differentiation of HSCs, followed by egress of mature progeny into the
circulating blood. HSCs are often vulnerable to mutagenesis arising from attenuated DNA repair and
DNA damage responses, but DNA damage can activate p53, thereby inhibiting cell cycle to promote
quiescence in damaged HSCs and to induce apoptosis of genetically injured HSCs [2]. Consequently,
p53 can maintain the integrity of HSC pool in a cell-autonomous manner. In addition to p53, HSC fate
is also controlled by local microenvironments including niche, which can deliver regulatory signals in
the form of bound or secreted molecules and from physical cues such as oxygen tension and shear
stress [1]. Among the regulatory signals, the interaction between a chemokine, CXCL12, and its
receptor, CXCR4, has emerged as an important regulator of normal hematopoiesis [1,3].
Genetic events occur in self-renewing HSCs in the case of chronic phase chronic myeloid
leukemia (CML) and most cases of acute myeloid leukemia (AML), or in early hematopoietic
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progenitor cells (HPCs) in a proportion of AML, such as granulocyte-macrophage progenitors in and
a granulocyte-macrophage progenitor-like subset in blast crisis CML [4]. Nevertheless, such genetic
events result in the generation of the disease-propagating leukemia cells, referred to as leukemic stem
cells (LSCs), which can self-renew, proliferate and differentiate, as can normal HSCs. Evidence is
accumulating to indicate that LSCs needs the signals delivered by bone marrow microenvironments
including niche cells for their initiation, maintenance, and proliferation [4]. Among the signals,
the CXCL12–CXCR4 axis can be an important signal pathway in local environment-mediated
leukemogenesis [4]. Moreover, the crosstalk between LSCs and bone marrow microenvironments is
presumed to be involved in some instances of therapeutic resistance [5]. Thus, the interaction between
LSCs and bone marrow microenvironments can be a novel target to treat CML.
Here, after briefly reviewing normal hematopoiesis, CML, and chemokines in normal
hematopoiesis, we will discuss the roles of chemokines in CML.
2. Results
2.1. Normal Hematopoiesis and Niche
Like the stem cells in other organs, HSCs under resting conditions divide in an asynchronous
manner to keep the total pool of HSCs approximately at the same levels [6]. Accordingly, an HSC
undergoes simultaneously a process of self-renewal and one of differentiation down the committed
progenitor pathway. Until now, important insights have been made to identify the molecules involved
in this stem cell fate, including CXCL12 [7], stem cell factor (SCF) [8], Notch [9], Sonic hedgehog [10],
Wnt [11], and transforming growth factor (TGF)-β [12]. These molecules are produced mostly by
non-hematopoietic cells present in bone marrow microenvironment, together with additional secreted
molecules and those expressed on cell surface. Thus, synthetic culture environment cannot completely
recapitulate bone marrow microenvironment; consequently, a large-scale ex vivo expansion of HSCs
has been very difficult to succeed by present.
HSCs are presumed to be localized in restricted areas in bone marrow, similarly observed on
stem cells in other organs such as skin and intestine [13]. These restricted areas are called as niches,
which are a functional unit to control stem cell number, fate, and behavior. Histological analysis
on bone marrow tissue revealed that many HSCs were associated with sinusoidal endothelium in
bone marrow, but some were associated with arterioles and endosteum (Figure 1) [1,14,15]. HSCs
are mobile, regularly entering and existing in circulation [16]; therefore, it cannot be ruled out that
these features can just mirror the transient presence of migrating HSCs in these areas. However,
the sequential high-resolution imaging of mice indicated that HSCs trafficked to selected regions of
bone marrow blood vessels abundantly expressing CXCL12 and E-selectin, and remained in these areas
for weeks, eventually generating new cells [17]. These observations would indicate that perivascular
and endosteal regions are hematopoietic niche and that CXCL12 has a crucial role by retaining HSCs
in these niches (Figure 2).
WHIM (wart, hypogammaglobulinemia, recurrent infections, and myelokthexis) syndrome is
an autosomal dominant combined primary immunodeficiency disease caused by loss of function
mutations in CXCR4 [18]. WHIM patient-derived HSCs exhibited a remarkable competitive
repopulating advantage over normal HSCs, without apparent deficits in engraftment [19]. These
observations would indicate that CXCL12 could inhibit HSC proliferation. This notion can be
corroborated by the observation that CXCL12 could in vitro inhibit entry of primitive hematopoietic
cells into the cell cycle, and inactivation of its receptor CXCR4 in HSCs caused excessive HSC
proliferation [20]. Moreover, the CXCR4−/− HSCs were able to in vivo maintain a stable stem cell
compartment and sustain hematopoiesis. Thus, the CXCR4–CXCL12 axis may be essential to keep
HSC quiescence, thereby maintaining a lifelong steady pool of HSCs to sustain the highly regenerative
hematopoietic system.
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Figure 1. Schematic structure of hematopoietic niche. Hematopoietic stem cells (HSCs) are found 
adjacent to sinusoids and arterioles throughout the bone marrow. In sinusoids, endothelial cells, 
CXCL12-abundant reticular (CAR) cells, and NestindimLepr+ perivascular cells promote HSC 
maintenance. NestinbrightNG+ perivascular cells adjacent to arterioles support HSCs. Sympathetic cells 
contribute to HSC maintenance by directly regulating CXCL12 expression by MSCs. Hematopoiesis 
can also be regulated by other types of cells such as osteoblasts. Arrows and “T” indicate stimulating 
and suppressive activities, respesctively. 
 
Figure 2. Presumed roles of CXCL12 in normal hematopoiesis. CXCL12 is produced by various types 
of cells in bone marrow, such as endothelial cells, mesenchymal stroma cells (MSCs), and CAR cells. 
stromal-derived factor (SDF), HSCs are maintained and retained by CXCL12 produced by Lepr+ 
perivascular cells in sinusoids or NG2+ perivascular cells in arterioles, while lymphoid progenitor 
cells are maintained by osteoblast-derived CXCL12. In addition, CXCL12 regulates the development 
of vasculature, which is crucial for hematopoietic functions. 
The localization of HSCs near blood vessels focused attention on endothelial cells as well as 
mesenchymal stroma cells (MSCs) that surround blood vessel throughout the bone marrow in terms 
of normal HSC physiology [1]. These MSCs are likely to be heterogeneous but can be defined as the 
cells expressing CD146 in humans [21], and SCF and CXCL12 were produced by MSCs as well as 
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The localization of HSCs near blood vessels focused attention on endothelial cells as well as
mesenchymal stroma cells (MSCs) that surround blood vessel throughout the bone marrow in terms
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of normal HSC physiology [1]. These MSCs are likely to be heterogeneous but can be defined as
the cells expressing CD146 in humans [21], and SCF and CXCL12 were produced by MSCs as well
as endothelial cells [3]. MSCs include NestindimLeptin Receptor-positive (Lepr+) perivascular cells
adjacent to sinusoids and Nestinbright nerve/glial antigen-positive 2 (NG2+) perivascular cells adjacent
to arteiroles (Figure 1) [1,15]. Moreover, adipogenic progenitor cells with a reticular shape, abundantly
express CXCL12 and consequently are named as CXCL12-abundant reticular (CAR) cells (Figure 1) [22].
Furthermore, many HSCs are in close contact with these CAR cells, suggesting that these CAR cells
can also contribute to hematopoiesis.
Ding et al. reported that HSCs were depleted from bone marrow when the SCF gene was
deleted from endothelial cells or Lepr+ perivascular cells but not hematopoietic cells, osteoblasts,
or nestin-expressing cells [23]. They further demonstrated that most HSCs were lost when the SCF
gene was deleted from both endothelial and Lepr+ perivascular cells. Thus, endothelial cells and
perivascular cells can support HSC proliferation by producing a potent growth factor, SCF (Figure 1).
Moreover, Asada et al. demonstrated that selective CXCL12 gene deletion from arteriolar NG2+,
but not from sinusoidal Lepr+ perivascular cells, reduced HSC and changed HSC localization in
bone marrow [24]. They further observed that SCF gene deletion in Lepr+, but not that in NG2+ cells,
reduced the HSC number in bone marrow. Thus, it is presumed that perivascular cells can differentially
and cooperatively contribute to HSC maintenance in bone marrow.
The crucial roles of CXCL12 in normal hematopoiesis is evidenced by remarkable phenotypic changes
in hematopoietic systems in the mice deficient in CXCL12 or CXCR4 genes [25–28], but these studies
did not give a clear outline of which cell type has an indispensable role in hematopoiesis by producing
CXCL12, because CXCL12 is primarily expressed by a wide variety of cells including perivascular
MSCs, endothelial cells, CAR cells, osteoblasts, and some hematopoietic cells [29,30]. Several groups
independently reported the effects of cell-type-specific CXCL12 gene deletion on the HSC number and
functions, but the results are not consistent, probably due to the incomplete gene deletion [24,29–31].
Omatsu et al. reported that short-term ablation of CAR cells in vivo impaired only the adipogenic
and osteogenic differentiation potential of marrow cells [30]. However, HSCs from CAR cell-depleted
mice were reduced in number and cell size, were more quiescent, and had increased expression
of early myeloid selector genes, similar to the phenotype of wild-type HSCs cultured without a
niche. Greenbaum et al. reported that deletion of the CXCL12 gene from CAR cells and osteoblasts
resulted in constitutive HPC mobilization and a loss of B-lymphoid progenitors, with normal HSC
function [31]. Moreover, CXCL12 gene deletion from endothelial cells resulted in a modest loss of
long-term repopulating activity, and deletion of CXCL12 from Prx1+ cells was associated with a marked
loss of HSCs, long-term repopulating activity, HSC quiescence, and common lymphoid progenitors.
Thus, CXCL12 expression in stromal cells in the perivascular region can support HSCs. Ding et al.
reported that deletion of CXCL12 from perivascular stromal cells depleted HSCs and certain restricted
progenitors and mobilized these cells into circulation and that deletion of CXCL12 from endothelial
cells depleted HSCs but not myeloerythroid or lymphoid progenitors [29]. In contrast, deletion of
CXCL12 from osteoblasts depleted certain early lymphoid progenitors but not HSCs or myeloerythroid
progenitors and did not mobilize these cells into circulation. However, deletion of CXCL12 gene
from hematopoietic cells or nestin-cre-expressing cells had little or no effect on HSCs or restricted
progenitors. Asada et al. demonstrated that CXCL12 or SCF gene deletion in all perivascular cells
dramatically reduced HSCs and that the reduced NG2+ cell- but not Lepr+ cell-derived CXCL12
decreased HSC numbers and altered HSC localization in bone marrow [24]. Collectively, Lepr+ and
NG2+ perivascular cells can maintain and retain HSCs cooperatively by producing CXCL12, while
osteoblast-derived CXCL12 can mainly contribute to the maintenance of lymphoid progenitors [1,15]
(Figure 2).
CXCL12 levels in bone marrow fluctuated in a circadian rhythm, through circadian adrenergic
signals [32]. These adrenergic signals were locally delivered by nerves in the bone marrow and
were transmitted to stromal cells by the β3-adrenergic receptor, leading to a decreased nuclear Sp1
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transcription factor and the rapid downregulation of CXCL12. Depressed CXCL12 attenuated the
retention of HSCs and their progenitors in bone marrow, culminating in the migration of these cells
into circulation in a circadian rhythm. Thus, the nervous system may be able to regulate hematopoiesis
through its effects on CXCL12, a master molecule for bone marrow niche functions (Figure 1).
2.2. Chemokines in Normal Hematopoiesis
Chemokines are a superfamily of chemotactic cytokines consisting of more than 40 structurally
related molecules (Table 1) [33]. Chemokines exert their biological functions through binding their
cognate 7-transmembrane spanning receptors coupled with heterotrimeric GTP-binding proteins [33].
Thus, the target cell specificity of each chemokine is determined mainly by the expression pattern
of its corresponding receptor. Chemokines exhibit a similar three-dimensional structure [34].
Triple-stranded β sheets are shaped by two intramolecular disulfide bonds, which are formed between
the first and third cysteines and between the second and fourth cysteines. The carboxy-terminal
region forms an α-helix with the capacity to bind heparin, which accounts for the ability of
chemokines to bind to proteoglycans and glycosaminoglycans with a high avidity. Consequently, most
chemokines are produced as secretory proteins, but once being secreted, they can be immobilized on
endothelium and extracellular matrix by interacting with proteoglycans and glycosaminoglycans [34].
The immobilization facilitates the generation of a concentration gradient, which is crucial for inducing
the target cells to migrate in a directed way.
Chemokines are divided into four subclasses; CXC, CC, CX3C, and C (Table 1) [33]. The first
cysteines are separated by one and three amino acids in CXC and CX3C chemokines, respectively,
while the first two cysteines are adjacent in CC chemokines. The single C chemokine does not possess
the second and fourth cysteines. Systemic nomenclature is based on their cysteine subclass roots,
followed by “L” for ligand and the numbers correspond to the number used in the corresponding gene
nomenclature. As most chemokine receptors can bind to a single chemokine subclass, the nomenclature
system of chemokine receptors is rooted by the chemokine subclass specificity, followed by “R”
for receptor and the corresponding number. The CXC chemokines can be further grouped on the
presence or the absence of a 3-amino acid sequence, glutamic acid-leucine-arginine (the “ELR” motif),
immediately preceding the CXC sequence [35]. In general, CXC chemokines with the ELR motif exhibit
a neutrophil chemotactic and an angiogenic activity by binding with their specific receptors, CXCR1
and/or CXCR2.
Based on their expression pattern, chemokines can be arbitrarily classified as inflammatory or
homeostatic [36]. Inflammatory chemokines are abundantly expressed under various inflammatory
conditions and can regulate the infiltration of inflammatory cells including granulocytes and
monocyte/macrophages. Representative inflammatory chemokines include CXC chemokines
with the ELR motif with a potent neutrophil chemotactic activity and CCL2 with a potent
monocyte/macrophage chemotactic activity. In contrast, homeostatic chemokines are expressed
constitutively in specific tissues or cells, and can regulate organogenesis of various organs.
CXCL12 is a representative homeostatic chemokine and is expressed constitutively in normal bone
marrow [25]. As we discussed in the previous section, CXCL12 is expressed in diverse types of cells in
adult bone marrow, including osteoblasts, endothelial cells, nestin-expressing cells, and adipogenic
progenitor cells, CAR cells. Moreover, CXCL12 has overlapping but distinct impacts on hematopoiesis,
by retaining HSCs in the bone marrow niche [17] and inhibiting cell cycle entry of HSCs to keep the
pool of quiescent HSCs [20] (Figure 2). In addition to its direct effects on the bone marrow niche
and HSCs, CXCL12 can indirectly have impacts on hematopoiesis. The defect of vessel development
in mice lacking CXCR4 [26] indicates that the CXCL12–CXCR4 axis may be able to indirectly affect
hematopoiesis, by regulating the development of vasculature, which can have a crucial effect on the
hematopoietic niche residing near vasculature (Figure 1).
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Table 1. Summary of chemokines and their receptors.
Standard Name Common Alias Receptor SCI Activity
CXCL1 groα, melanoma growth stimulating activity (MGSA), KC CXCR2
CXCL2 groβ, macrophage inflammatory protein (MIP)-2α CXCR2 +
CXCL3 groγ, MIP-2β CXCR2
CXCL4 platelet factor-4 (PF-4) CXCR3 +
CXCL5 epithelial neutrophil activating peptide (ENA)-78 CXCR2 > CXCR2 +
CXCL6 granulocyte chemotactic protein (GCP)-2 CXCR1, CXCR2 +
CXCL7 neutrophil activating protein (NAP)-2 CXCR2
CXCL8 interleukin-8 (IL-8) CXCR1, CXCR2 +
CXCL9 monokine induced by interferon γ (Mig) CXCR3 +
CXCL10 interferon inducible protein (IP)-10 CXCR3 +
CXCL11 interferon inducible T-cell α chemoattractant (I-TAC) CXCR3, CXCR7
CXCL12 stromal-derived factor (SDF)-1 CXCR4, CXCR7 +
CXCL13 B lymphocyte chemoattractant (BLC) CXCR5
CXCL14 breast and kidney expressed chemokine (BRAK) ?
CXCL15 lungkine ?
CXCL16 scavenger receptor for phosphatidylserine and oxidized lipoprotein (SR-PSOX) CXCR6
CXCL17 ?
CCL1 I-309 CCR8 +
CCL2 monocyte chemoattractant (MCP)-1 CCR2 +
CCL3 MIP-1α CCR1, CCR5 +
CCL4 MIP-1β CCR5 > CCR1
CCL5 regulated upon activation normal T cell expressed and secreted (RANTES) CCR1, CCR5, CCR3
CCL6 C10, macrophage inflammatory protein-related protein (MRP)-1 ? +
CCL7 MCP-3 CCR1,CCR2, CCR3 > CCR5
CCL8 MCP-2 CCR2, CCR1, CCR3, CCR5
CCL9 MRP-2, MIP-1γ ? +
CCL10 ? +
CCL11 eotaxin CCR3 > CCR5 +
CCL12 MCP-5 ? +
CCL13 MCP-4 CCR1,CCR2, CCR3 > CCR5 +
CCL14 hemofiltrate CC chemokine (HCC)-1 CCR1
CCL15 HCC-2 CCR1, CCR3 +
CCL16 HCC-4 CCR1, CCR2, CCR5 +
CCL17 thymus and activation-regulated chemokine (TARC) CCR4 > CCR8
CCL18 pulmonary and activation-regulated chemokine (PARC) ? +
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Table 1. Cont.
Standard Name Common Alias Receptor SCI Activity
CCL19 EBI1-ligand chemokine (ELC) CCR7 +
CCL20 MIP-3α, liver and activation-related chemokine (LARC) CCR6 +
CCL21 secondary lymphoid chemokine (SLC) CCR7 +
CCL22 macrophage-derived chemokine (MDC) CCR4
CCL23 myeloid progenitor inhibitory factor-1 (MPIF-1) CCR1 +
CCL24 eotaxin-2 CCR3 +
CCL25 thymus-expressed chemokine (TECK) CCR9 +
CCL26 eotaxin-3 CCR3
CCL27 cutaneous T-cell attracting chemokine (CTACK) CCR10
CCL28 mucosae-associated epithelial chemokine (MEC) CCR3, CCR10
XCL1 lymphotaxin-α XCR1 +
XCL2 lymphotaxin-β XCR1 +
CX3L1 fractalkine CX3CR1
“?” in receptor column indicates that the receptor is unidentified; “+” in SCI activity column indicate that the chemokine can exhibit SCI activity.
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The HSC pool in bone marrow is stably maintained by an intricate balance between differentiation,
self-renewal, and reversible quiescent cell cycle arrest of HSCs. During the 1970s and 1980s, a molecule
present in bone marrow microenvironment has been presumed to regulate steady-state quiescent arrest
of HSCs and has been named a stem cell inhibitor (SCI) (Table 1) [37]. One candidate for this stem cell
inhibitor can be CXCL12, since CXCL12 can in vitro inhibit entry of primitive hematopoietic cells into
the cell cycle, and inactivation of its receptor CXCR4 in HSCs causes excessive HSC proliferation [20].
Another candidate for SCI is CCL3 because it can reversibly inhibit colony formation and
proliferation of hematopoietic stem/progenitor cells (HSPCs) both in vitro and in vivo [38–40].
Moreover, CCL3 can maintain a quiescent state in HSCs by blocking cell cycle entry [41]. In contrast,
CCL3 can activate the proliferation of more mature progenitor cells [39,42]. Indeed, CCL3 was
expressed constitutively by normal basophils present in normal bone marrow [43]. Moreover,
the genetic deletion of CCL3 gene in donor cells caused exaggerated reconstitution of donor-derived
hematopoietic cells upon bone marrow transplantation. Furthermore, deletion of basophils
recapitulated similar phenotypes upon bone marrow transplantation [43]. Thus, CCL3 produced
by basophils may be able to act as SCI to dampen the proliferation of normal HSPCs (Figure 3).
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generated from LICs and produce abundantly CCL3, which inhibits normal HSPC proliferation to 
confer growth advantage to LICs over normal HSPCs. Black arrows indicate the differentiation 
pathways while the red arrow indicate the competition between normal HSCs and LICs. “T” 
indicates the suppressive activities. 
There are more than 20 chemokines that have been found to suppress HSPC proliferation in a 
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CCL11, CCL12, CCL13, CCL15, CCL16, CCL18, CCL19, CCL20, CCL21, CCL23, CCL24, CCL25, and 
XCL1. However, except CXCL12 and CCL3, the suppressive effects of these chemokines have not yet 
been examined extensively. 
Granulocyte colony-stimulating factor (G-CSF) has been clinically used to mobilize HSPCs into 
peripheral blood and to use them for hematopoietic transplantation [46]. This success spurred the 
investigation on the ability of other cytokines and chemokines to mobilize HSPCs into peripheral 
blood. In fact, CCL3 preferentially mobilized the more primitive progenitors with marrow 
repopulating activity, releasing four times the number achieved with G-CSF alone [47], by 
interacting mainly with CCR1 but not CCR5, among its specific receptors [48]. Multiple ligands for 
CXCR2, CXCL1, CXCL2, and CXCL8 also rapidly mobilized HSPCs with long-term repopulating 
Figure 3. Presumed roles of CCL3 in chronic myeloid leukemia (CML). A small amount of CCL3 with
a potent inhibitory activity for normal HSPCs is produced constitutively by basophils under normal
circumstances. In CML bone marrow, a large number of basophil-like leukemia cells are generated
from LICs and produce abundantly CCL3, which inhibits normal HSPC proliferation to confer growth
advantage to LICs over normal HSPCs. Black arrows indicate the differentiation pathways while the red
arro indicate the competition between normal HSCs and LICs. “T” indicates the suppressive activities.
There are more than 20 chemokines that have been found to suppress HSPC proliferation in a
manner similar to that of CCL3 (Table 1) [44,45]. The list crosses the CC, CXC, and C subfamily and
includes CXCL2, CXCL4, CXCL5, CXCL6, CXCL8, CXCL9, CXCL10, CCL1, CCL2, CCL6, CCL9/10,
CCL11, CCL12, CCL13, CCL15, CCL16, CCL18, CCL19, CCL20, CCL21, CCL23, CCL24, CCL25,
and XCL1. However, except CXCL12 and CCL3, the suppressive effects of these chemokines have not
yet been examined extensively.
Granulocyte colony-stimulating factor (G-CSF) has been clinically used to mobilize HSPCs into
peripheral blood and to use them for hematopoietic transplantation [46]. This success spurred the
investigation on the ability of other cytokines and chemokines to mobilize HSPCs into peripheral
blood. In fact, CCL3 preferentially mobilized the more primitive progenitors with marrow repopulating
activity, releasing four times the number achieved with G-CSF alone [47], by interacting mainly with
CCR1 but not CCR5, among its specific receptors [48]. Multiple ligands for CXCR2, CXCL1, CXCL2,
and CXCL8 also rapidly mobilized HSPCs with long-term repopulating ability into peripheral blood
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in mice and monkeys [49–52]. However, CXCR2 was not expressed on HSC and HPC [53]. Detailed
analysis indicated that neutrophils were a common target for HSPC mobilization induced by CXCR2
ligands and G-CSF and that this mobilization was mediated by neutrophil-derived plasma matrix
metalloproteinase (MMP)-9 [52]. However, how MMP-9 can mobilize HSPCs still remains elusive.
A CXCR4 agonist [54] and a CXCR4 antagonist [55] have similarly mobilized alone or
synergistically with G-CSF. These apparently puzzling effects can be explained by depressed CXCR4
expression by HSPCs by the treatment with a CXCR4 agonist or antagonist. Considering the crucial
roles of the CXC12–CXCR4 axis in HSPC maintenance in bone marrow [25–28], depressed CXCR4
expression on HSPCs may be able to reduce the interaction between HSPCs and CXCL12-expressing
niche and subsequent HSPC migration from bone marrow.
The crucial involvement of the CXCL12–CXCR4 axis in normal hematopoiesis is substantiated
by remarkable phenotypic changes in hematopoietic systems in the mice deficient in CXCL12 or
CXCR4 [25–28]. Among mice deficient in other chemokine and chemokine receptor genes, mice
deficient in either CCL5 or atypical chemokine receptor (ACKR)1, also known as Duffy antigen
receptor for chemokines (DARC) [56], exhibited abnormalities in HSCs. Enhanced CCL5 expression
in aging stem cell milieu was associated with myeloid skewing and reciprocally, CCL5-deficient
mice exhibited a decrease in myeloid-biased HSCs and an increase in T cell and lymphoid-biased
HSCs in a cell-autonomous manner [57]. These observations suggested that aging-related changes in
hematopoietic functions can arise from aging-related augmented CCL5 expression in bone marrow.
ACKR1 is a sink receptor for various chemokines because it can bind various chemokines
including both CXC and CC chemokines without transducing any intracellular signal [56]. Nucleated
erythroid cells expressed abundantly ACKR1, which facilitated their direct contact with HSCs,
and the absence of ACKR1 decreased HSPCs and alters their differentiation with aberrant neutrophil
dysfunction [58]. Of interest is that neutrophil abnormalities were observed in Duffy antigen-negative
persons. However, it is an open question which chemokine(s) is involved in phenotypic changes
observed in ACKR1 deficiency.
2.3. CML
CML is a myeloproliferaive disorder arising from the malignant transformation of HSCs in
chronic phases or of HPCs in the blast crisis phase [4]. It harbors a characteristic chromosomal
abnormality, the Philadelphia chromosome, which results from a reciprocal translocation between the
long arms of chromosome 9 (ch9) and 22 (ch22) [59]. t (9,22) causes the juxtaposition of the ABL-1
gene, the human analogue of the v-ABL oncogene, from ch9 with the BCR housekeeping gene on
ch22 to produce the fusion of the BCR-ABL gene, which can be translated to BCR-ABL protein. ABL-1
encodes a non-receptor tyrosine kinase that phosphorylates substrate proteins through its SH1 domain,
and eventually has profound impacts on crucial cellular activities, leading to increased cell proliferation
and resistance to apoptosis [60]. When BCR-ABL fusion gene is generated, the upstream control element
of the ABL-1 gene is deleted and is replaced with the BCR gene. As a consequence, BCR-ABL protein is
capable of phosphorylating constitutively itself, resulting in uncontrolled activation of a wide variety
of downstream effector pathways and the transformation of HSCs into LSCs, which can behave in
leukemogenic hematopoiesis, as do HSCs in normal hematopoiesis. Moreover, CML cells depend on
their own BCR-ABL’s constitutive tyrosine kinase activity for their autonomous proliferation, and
BCR-ABL protein is selectively expressed in CML cells but not normal cells including hematopoietic
cells. Due to these characteristics, BCR-ABL protein has been a preferable druggable target [59,60].
The clinical application of imatinib, a relatively selective inhibitor for BCR-ABL’s tyrosine kinase,
has transformed CML, a thitherto intractable disease, into a controllable one [59]. Subsequent
development of additional tyrosine kinase inhibitors (TKIs) further improved the prognosis of CML
patients. However, a long-term treatment with TKIs frequently fails to eradicate CML cells; as a
consequence, the discontinuation of TKIs can cause CML recurrence even if BCR-ABL gene expression
cannot be detected for a considerable period with the most sensitive molecular biological methods [61].
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BCR-ABL can promote LSC and their progeny survival through its kinase-independent activities such
as modulation of Hedgehog and BRCA1 pathways, the activities that cannot be inhibited by TKIs [62].
This may account partly for the failure of TKIs to eradicate LSCs and eventually cure CML. In addition
to these leukemia cell-autonomous mechanisms, the resistance to TKIs can arise from the effects of
various factors, which are produced by bone marrow microenvironments to help LSCs survive TKIs,
and TGF-β can be one of the growth factors that can confer growth advantage on LSCs during TKI
treatment [63].
At both the initiation phase and the TKI-induced remission stage of CML, a small number of
BCR-ABL-expressing LSCs are present at one site in bone marrow, where normal hematopoietic cells
including hematopoietic stem/progenitor cells (HSPCs) are abundant [62]. LSCs are presumed to
compete for hematopoietic niche with normal hematopoietic cells in the primary bone marrow site.
After LSCs predominate over normal hematopoietic cells to occupy one bone marrow site, they can
infiltrate other bone marrow sites and the spleen, and they can finally appear in peripheral blood as
they differentiate into the leukemic cells with more mature phenotypes. The analysis on mathematical
models, which were constructed by using Bayesian inference techniques, supported the notion that
clinical outcome in CML could be determined by the competition over niche between normal HSPCs
and LSCs [64].
Simultaneously, evidence is accumulating to indicate that LSC maintenance and subsequent
CML development require the cues provided by the bone marrow niche [62]. In fact, TGF-β and its
related molecules, bone morphogenetic protein 2 (BMP2) and BMP4, were expressed by the bone
marrow niche, and can promote CML cell expansion [65,66]. Moreover, homing and engraftment of
BCR-ABL-expressing LSCs required E-selectin expression by the bone marrow endothelial niche [67].
Collectively, although BCR-ABL can confer the autonomous growth capacity on LSCs, subsequent
CML development and the responsiveness to drugs can be markedly modulated by signals provided
by bone marrow microenvironments, particularly the hematopoietic niche.
2.4. CXCL12 in CML
In transgenic mice with inducible BCR-ABL gene, its induction can cause chronic phase CML [68].
In this CML model, LSCs were restricted to cells with long-term hematopoietic stem cell (LTHSC)
phenotype. CML LTHSC demonstrated reduced homing and retention in the bone marrow and
increased egress to spleen. These changes were associated with decreased CXCL12 expression
in bone marrow and reciprocally increased CXCL12 expression in the spleen [68]. In line with
these observations, CML cell-derived exosome delivered miR-126 to reduce CXCL12 expression
in endothelial cells [69]. Of interest is that CML LSCs were characterized by a specific expression of
a surface expression of dipeptidylpeptidase-IV, which can cleave CXCL12 and reduce its biological
activities [70]. Thus, CML cells may be able to reduce functional CXCL12 expression in the cells
surrounding them, to facilitate their egress from bone marrow to other sites including spleen and
peripheral blood.
Depressed CXCL12 expression in CML bone marrow can arise from an additional mechanism.
CML bone marrow exhibited increased levels of several cytokines and chemokines including IL-1α,
IL-1β, IL-6, G-CSF, TNF-α, CCL3, and CCL4 [68]. Among these cytokines and chemokines, only
G-CSF in vitro decreased CXCL12 expression in bone marrow stromal cells, while anti-G-CSF antibody
treatment increased CXCL12 expression and CML LSC numbers in bone marrow, and reciprocally
decreased CML LSC numbers in the spleen [68]. Similar changes were observed when CML mice
are treated with a TKI, imatinib. Moreover, human CML bone marrow exhibited decreased CXCL12
and increased G-CSF expression [68]. These observations would indicate that CML cells, particularly
LSCs, can be retained in bone marrow by the action of CXCL12, which may be under the control
of the cytokine network consisting of G-CSF and other pro-inflammatory cytokines. Moreover,
reduced CXCL12-mediated signals may be able to induce the egress of CML cells, particularly LSCs,
to extra-bone marrow sites, thereby promoting CML progression.
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CXCL12 may be able to elicit similar concentration-dependent growth suppressive effects on
normal and CML CD34+ cells in colony-forming cell assays, but no significant differences were
observed on CXCR4 expression and responsiveness to CXCL12-induced increases in intracellular
calcium levels between normal and CML CD34+ cells [71]. However, human CD34+ CML cells
in peripheral blood showed a reduced migratory response to CXCL12, compared with human
normal CD34+ cells [71]. Moreover, human BCR-ABL+CD34+CXCR4+ cells displayed reductions
in CXCL12-induced integrin-dependent polarization and migration, and binding to vascular cell
adhesion molecule-1 or fibronectin, compared with normal CD34+CXCR4+ cells [72]. Comprehensive
gene expression analysis revealed depressed CXCR4 mRNA expression in CML CD34+ cells, compared
with normal CD34+ cells, but the study did not examine the cell surface expression levels [73]. Chang
and colleagues, however, proposed that the impaired chemotactic response of CML CD34+ cells to
CXCL12 might be due to an intracellular signaling defect downstream of the receptor. This notion may
be supported by the observations that BCR-ABL could persistently activate Cdc42 GTPase, which is
crucially involved in cytoskeletal remodeling and directional sensing, and that its sustained activation
reduced CXCL12-mediated chemotactic response by desensitizing the actin polarization required for
directional migration [74].
Evidence is accumulating to indicate that LSCs are rather resistant to various chemotherapeutic
drugs and TKIs through the interaction with hematopoietic niche [75]. The CXCL12–CXCR4 axis may
have profound effects on the interaction of CML cells with hematopoietic niche consisting of extracellular
matrix and stromal cells in bone marrow. A TKI, imatinib, enhanced CXCR4 expression in CML cells and
caused the migration of CML cells to the CXCL12-expressing bone marrow microenvironment niche,
which provided CML cells with anti-apoptotic signals and subsequently resistance to imatinib [76].
It also promoted CXCR4 redistribution in CML cells into the lipid raft fraction, where it co-localized with
active phosphorylated form of a src-related kinase, Lyn [77]. Through these compartmental changes
of multivalent CXCR4 and activated Lyn complexes, CML cells migrated to the bone marrow niche,
where they survived despite the presence of imatinib. Likewise, the resistance to another TKI, nilotinib,
was associated with CXCR4-mediated adhesion of CML cells to extracellular matrix components and
bone marrow stromal cells [78]. These observations would indicate that the CXCL12–CXCR4 axis could
prevent CML cells from apoptosis by enhancing the interaction of these cells with hematopoietic niche,
which could confer growth-promoting and/or anti-apoptotic signals.
CXCR4 directly delivered growth-promoting and/or anti-apoptotic signals to CML cells. CXCR4
activated its downstream PI3K/Akt signal pathway and promoted the translocation of NF-κB
complexes into nucleus in CML cells, thereby decreasing the expression of apoptosis-related
molecules [79]. CXCL12 conferred the resistance to adriamycin on CML cells by augmenting their
CXCR4 expression and CXCR4 siRNA treatment can partially reduce adriamycin resistance [79].
Moreover, CXCL12 activated pro-survival signal pathways including extracellular signal-regulated
kinase (Erk)-1/2, Akt, S-6-kinase, STAT3, and STAT5, and in vitro treatment with a CXCR4 antagonist
directly inhibited cell growth and induced eventually cell death [80]. Furthermore, CXCL12 increased
the expression of ABC transporters including multidrug resistance 1, ATP-binding cassette subfamily
C member 1 (ABCC1), and ATP-binding cassette subfamily G member 2 (ABCG2) [81], and their
enhanced expression might substantially contribute to resistance to chemotherapeutic agents by
exporting chemotherapeutic drugs outside cells.
The roles of the CXCL12–CXCR4 axis in CML cell survival prompted several groups to examine
the therapeutic efficacy of CXCR4 antagonists for CML in preclinical models. A CXCR4 antagonist,
plerixafor, had no effects on CML progression in mice intravenously injected with BCR-ABL-transduced
mouse 32D cells, but its combination with nilotinib significantly delayed time to relapse, and
significantly prolonged survival when compared with nilotinib monotherapy, without any significant
effects on the body weights of the mice [78]. Another CXCR4 antagonist, BKT140, effectively reduced
the growth of the tumors arising from subcutaneous injection of a human CML cell line, K562, and its
combination with imatinib essentially abrogated tumor growth, resulting in 95% reduction in tumor
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size and weight, together with extensive necrotic tissue damage [80]. However, these models used
a cloned cell line as a source of CML cells, so the observations need to be extrapolated with caution.
When CML was induced by bone marrow transplantation with BCR-ABL-expressing hematopoeitic
cells, the combined treatment with plerixafor and TKIs failed to reduce leukemia burden over TKIs
alone [82]. Moreover, mice receiving plerixafor had an increased incidence of neurologic symptoms in
association with BCR-ABL-expressing cell infiltration into the central nervous system, probably arising
from a potent capacity of a CXCR4 antagonist to induce the egress of CML cells from bone marrow [82].
Thus, clinical application of a CXCR4 antagonist warrants more detailed and meticulous investigation.
2.5. CCL3 and Its Related Chemokines in CML
The identification of CCL3 as SCI incited several groups to examine its effects on CML cell
proliferation. Both TGF-β1 and CCL3 inhibited colony forming unit (CFU)-A colony formation from
normal hematopoietic cells, whereas TGF-β1 but not CCL3 inhibited CFU-A colony formation from
CML progenitor cells [83]. Likewise, the CML cell population exhibited an increased rate of turnover
at primitive clonogenic cell levels, due to an inability of CML cells to respond to the cytostatic effects
of CCL3 [84]. Moreover, the addition of CCL3 to normal long-term cultures of hematopoietic cells
reversibly and specifically blocked the activation of primitive progenitor with high proliferative
potential but not mature progenitor with lower proliferative potential [85]. On the contrary, CCL3
failed to block the cell cycling of primitive CML progenitors, when it was added to similar long-term
cultures containing normal bone marrow adherent cell layers but supporting CML hematopoiesis.
Nicholls et al. reported that CCL3 binding sites were reduced on CML CD34+ cells, compared with
normal CD34+ population and proposed that reduced CCL3 binding sites were responsible for reduced
responsiveness of CML progenitor cells to CCL3 [86]. Chasty et al., however, indicated the presence of
a single population of cells that expressed cell surface receptors for CCL3 independently of cell cycle
status [87]. They further proposed that CML progenitor cells might be refractory to CCL3 as a result of
events downstream from receptor expression. Consistently, Dürig et al. reported that normal and CML
CD34+ cells bound to biotinylated CCL3 to similar extents [88]. They further demonstrated that a specific
receptor for CCL3, CCR5, was expressed at comparable levels in normal and CML CD34+ cells. Our
analysis on the expression of CCL3 receptors, CCR1 and CCR5, revealed that CCR1 and to a markedly
lesser degree, CCR5, was expressed on normal lineage marker (lin)−c-kit+ progenitor cells and that CCR1
but not CCR5 expression was maintained by CML lin−c-kit+ progenitor cells [89]. Thus, decreased CCL3
receptor expression on CML progenitor cells cannot explain the inability of these cells to respond to CCL3.
This assumption is supported by the observations by Wark et al. [90]. They established a cell line
which can express temperature-sensitive ABL gene, from a growth factor-dependent multipotent stem
cell line, in which growth was normally suppressed by CCL3. When ABL expression was induced,
the cells lost the capacity to respond to CCL3 [90]. They further demonstrated that ABL expression did
not change the number and affinity of CCL3 binding sites on the cells but did abrogate CCL3-mediated
increases in intracellular Ca2+ concentrations. Thus, it is likely that ABL’s tyrosine kinase activity can
directly reduce the responsiveness to CCL3.
Murine CML-like disease can be induced by transferring human-derived BCR-ABL
gene-transduced primitive bone marrow cells intravenously to a lethally irradiated host [91]. This
model has been widely used, but in this model, lethal irradiation completely destructs the normal
hematopoietic microenvironment to enable BCR-BAL+ leukemic cells to home to the bone marrow
and grow therein. Thus, it is difficult to elucidate the role of bone marrow microenvironment in
CML development, particularly at its early phase. The other model utilizes an inducible BCR-ABL
transgenic mouse, which can express BCR-ABL gene in HSPCs in an inducible manner [92]. However,
in this model, it is not easy to selectively tag leukemia cells for the examination of leukemia cell
trafficking. In order to circumvent these problems, we established a novel CML model, by transferring
human-derived BCR-ABL gene-transduced primitive bone marrow cells to the bone marrow of
non-irradiated nude mice [89].
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In this model, the expression of CCL3 but not those of other chemokines were increased [89],
in contrast to the previous report that in addition to CCL3, CCL4, and CXCL12 expression was
enhanced in bone marrow of inducible BCR-ABL transgenic mice, which developed CML [68].
CCL3-deficient BCR-ABL-transduced HSPCs failed to induce CML-like phenotypes when injected
into the bone marrow of non-irradiated host, but induced CML-like phenotypes when transferred
intravenously into irradiated hosts [89]. Thus, CCL3 might have a role in CML development, only
when bone marrow microenvironment can be preserved. Consistently, normal HSPCs directly impeded
the maintenance of LSCs when these cells did not express either CCR1 and/or CCR5, the specific
receptors for CCL3 [89]. The potential roles of the interplay between CCL3 and its receptors may
be further supported by the observation that a CCR5 antagonist prevented CML development in
nude mice receiving intra-bone marrow injection of BCR-ABL+ leukemia cells, when it was initiated
immediately after the injection [43].
Detailed analysis on this model identified basophil-like leukemia cells and to a lesser degree,
normal basophils as a source of CCL3 in CML bone marrow [43]. Similar observations were obtained on
the bone marrow of patients with CML. Moreover, deletion of basophil-like leukemia cells recapitulated
the phenotypes observed when CCL3-deficient BCR-ABL-transduced HSPCs were injected into the
bone marrow of non-irradiated host [43]. Collectively, basophilia, a frequently observed hematological
abnormality in CML patients, may not simply be an accompanying phenomenon but may have a
pathogenic role in CML development, by producing abundantly CCL3, which can dampen normal
HSPC but not LSC proliferation, and eventually provide LSCs with a growth advantage over normal
HSPCs, particularly at the early phase of CML development (Figure 3). Thus, basophils and/or the
CCL3 axis can be a novel target for CML treatment.
CCL3 may cause myeloproliferative neoplasm (MPN) in a different manner. About half of
patients with Noonan syndrome harbor a germline activating mutations of the protein tyrosine
phosphatase src homology-2 domain containing protein tyrosine phosphatase (SHP2) (encoded by
PTPN11), a positive regulator of the RAS signaling pathway [93]. These patients have an increased
risk of developing leukemia, especially juvenile myelomonocytic leukemia (JMML), a childhood MPN.
Ptpn11 mutations in mesenchymal stem/progenitor cells and osteoprogenitors, but not in differentiated
osteoblasts or endothelial cells, caused excessive production of CCL3, which recruited monocytes to
the area where HSCs also reside [94]. Consequently, HSCs were hyperactivated by monocyte-derived
interleukin-1β and other proinflammatory cytokines, leading to the development of MPN, particularly
donor-cell-derived MPN following stem cell transplantation [94]. Thus, bone marrow stroma-derived
CCL3 may be able to cause leukemogenesis by inducing infiltration of monocytes with a capacity to
produce abundantly various pro-inflammatory cytokines and to eventually enhance the proliferation
of pre-leukemic cells.
2.6. Other Chemokines in CML
Evidence is accumulating to indicate the involvement of other chemokines in CML pathogenesis.
CXCL8 protein expression was enhanced by BCR-ABL expression and was inhibited by TKIs such as
dasatinib and nilotinib, implicating CXCL8 as a useful marker for the monitoring of CML inhibitor
efficacy [95]. The analysis on a human CML cell line, LAMA84, revealed that CML cell-derived
exosomes stimulated bone marrow stromal cells to produce CXCL8 that, in turn, was able to enhance
the capacity of CML cells to migrate and to adhere to stromal cells, and to promote CML cell
proliferation both in vitro and in vivo [96]. However, the effects of CXCL8 on other CML cell lines in
general remain elusive.
CCL2 blocked the cell cycle entry of normal HSPCs but not CML progenitor cells, whereas TGF-β
inhibited cell cycle entry of both normal HSPCs and CML LSCs [97]. Of interest is that comprehensive
analysis revealed enhanced CCL2 but reduced TGF-β expression in CML LSCs, compared with normal
HSPCs [98]. Thus, CCL2 and CCL3 can contribute to CML development in similar manners.
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BCR-ABL gene transduction into umbilical cord blood-derived CD34+ cells suppressed the
expression of a chemokine receptor, CCR7, as well as adhesion molecules such as L-selectin and
intercellular adhesion molecule (ICAM)-1 [99]. Moreover, depressed CCR7 expression was associated
with reduced migratory ability to its ligands, CCL19 and CCL21. On the contrary, Kubo et al. observed
that BCR-ABL cooperated with signal transducing adaptor protein (STAP)-2 to induce the expression
of CCR7 and CXCR4 and the production of the ligands for CCR7, CCL19, and CCL21, in a murine
hematopoietic BaF/3 cell [100], raising the possibility of the contribution of the CCR7 axis to CML cell
proliferation. Hromas et al., however, claimed that CCR7 ligands, CCL19 and CCL21, and a CCR6
ligand, CCL20, inhibited proliferation of CML progenitor cells as well as normal progenitor cells [101].
Collectively, the roles of the CCR7 axis in CML pathogenesis remain an open question.
3. Future Perspective
The identification of BCR-ABL gene as a driver mutation for CML has spurred the development
of TKIs targeting the tyrosine kinase activity of BCR-ABL fusion protein and the clinical application of
TKIs has remarkably improved the prognosis of CML patients [59,60]. TKIs mainly target leukemia
cells in cell cycle but LSCs usually stay dormant through the interaction with the bone marrow
microenvironment, particularly the niche [75]. As a consequence, even long-term treatment with
TKIs frequently fail to eradicate LSCs and to eventually cure CML [62]. Thus, in order to develop a
novel therapeutic strategy for CML, it is necessary to elucidate the cellular and molecular mechanisms
underlying the interaction between LSCs and bone marrow microenvironments.
As we discussed here, evidence is accumulating that indicates the crucial roles of chemokines,
particularly CXCL12 and CCL3, in CML progression [77,89]. More detailed analysis on the roles
of these chemokines can enable the development of a novel therapeutic strategy to supplement the
treatment with TKIs.
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